<DOC>
	<DOCNO>NCT01110031</DOCNO>
	<brief_summary>Ofatumumab fully-human monoclonal antibody exhibit high bind affinity antigen surface B lymphocytes . Antigen engagement ofatumumab result maximal B-cell kill complement-dependent cytotoxicity antigen-dependent cellular cytotoxicity antigen high- low-expressing cell . Recent research show ofatumumab-dependent B-cell depletion provide clinical benefit subject CD20-positive cancer chronic lymphocytic leukemia ( CLL ) . The purpose current study assess impact ofatumumab electrocardiographic parameter particular focus cardiac repolarization ( QTc interval duration ) subject refractory CLL . Subjects enrol open-label , single-arm trial receive ofatumumab high clinical dose ( 2000 mg ) study plan study . Ofatumumab administer eight weekly intravenous ( IV ) infusion follow four monthly infusion , begin Week 13 , across 25-week treatment period . Cardiovascular effect evaluate treatment routine 12-lead electrocardiographic ( ECG ) monitoring . The pharmacokinetic relationship plasma concentration ofatumumab effect QTc interval duration examine . Specifically , ECG assessment collect triplicate baseline , time maximum ofatumumab concentration periodically on-therapy , end treatment . After completion final ofatumumab infusion , subject continue follow safety efficacy six month relative last ofatumumab dose .</brief_summary>
	<brief_title>Ofatumumab Cardiac Repolarization ( QTc ) Study Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects</brief_title>
	<detailed_description>The purpose trial assess impact ofatumumab electrocardiographic parameter particular focus cardiac repolarization ( QTc interval duration ) subject refractory Chronic Lymphocytic Leukemia ( CLL ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Confirmed diagnosis Chronic Lymphocytic Leukemia ( CLL ) . Active CLL disease indication treatment . Previous treatment fludarabinecontaining treatment achieve least partial response , disease progression occur responder within six month last dose fludarabinecontaining treatment regimen . Fully active minimum , fully capable selfcare 50 % waking hour . Age 18 year old . Signed write informed consent . Acceptable level laboratory chemistry test potassium magnesium . Males female subject must agree use contraception ( fertile ) time first dose study medication one year follow last dose ofatumumab . Any abnormal electrocardiogram ( ECG ) cardiac conduction finding . Certain heart problem , chronic infection , serious significant disease . Known transformation CLL . CLL central nervous sytem involvement . Abnormal/inadequate blood value , liver , kidney function . Past current malignancy besides CLL , unless free malignancy least two year , history completely resect nonmelanoma skin cancer , successfully treat . Lactating woman woman positive pregnancy test . Use medication know prolong heart rhythm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>Cardiac Repolarization ( QTc )</keyword>
</DOC>